IN2014CN04127A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04127A
IN2014CN04127A IN4127CHN2014A IN2014CN04127A IN 2014CN04127 A IN2014CN04127 A IN 2014CN04127A IN 4127CHN2014 A IN4127CHN2014 A IN 4127CHN2014A IN 2014CN04127 A IN2014CN04127 A IN 2014CN04127A
Authority
IN
India
Prior art keywords
formula
triazol
115the
benzamide
pharmaceuticals
Prior art date
Application number
Other languages
English (en)
Inventor
Martin Bolli
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Jodi T Williams
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of IN2014CN04127A publication Critical patent/IN2014CN04127A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
IN4127CHN2014 2011-11-08 2012-11-07 IN2014CN04127A (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2011054976 2011-11-08
PCT/IB2012/056218 WO2013068935A1 (en) 2011-11-08 2012-11-07 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
IN2014CN04127A true IN2014CN04127A (uk) 2015-07-10

Family

ID=47258050

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4127CHN2014 IN2014CN04127A (uk) 2011-11-08 2012-11-07

Country Status (28)

Country Link
US (1) US9150566B2 (uk)
EP (1) EP2776430B1 (uk)
JP (1) JP5718535B2 (uk)
KR (1) KR101676930B1 (uk)
CN (1) CN103917538B (uk)
AR (1) AR088692A1 (uk)
AU (1) AU2012335194B2 (uk)
BR (1) BR112014010617B1 (uk)
CA (1) CA2846568C (uk)
CL (1) CL2014000659A1 (uk)
CY (1) CY1117638T1 (uk)
DK (1) DK2776430T3 (uk)
EA (1) EA024106B1 (uk)
ES (1) ES2572703T3 (uk)
HK (1) HK1199022A1 (uk)
HR (1) HRP20160678T1 (uk)
HU (1) HUE029239T2 (uk)
IL (1) IL232462A (uk)
IN (1) IN2014CN04127A (uk)
MX (1) MX343837B (uk)
MY (1) MY167791A (uk)
PL (1) PL2776430T3 (uk)
SG (1) SG11201401665WA (uk)
SI (1) SI2776430T1 (uk)
TW (2) TWI565703B (uk)
UA (1) UA112317C2 (uk)
WO (1) WO2013068935A1 (uk)
ZA (1) ZA201404189B (uk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
WO2013119639A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
DK3077389T3 (da) 2013-12-03 2017-11-13 Idorsia Pharmaceuticals Ltd Krystallinsk form af (s)-(2-(6-chlor-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanon og dens anvendelse som orexinreceptorantagonister
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
CN105814042B (zh) * 2013-12-13 2018-09-28 大正制药株式会社 噁嗪烷化合物的晶形及其制造方法
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
JP6323886B2 (ja) * 2014-05-16 2018-05-16 国立大学法人 東京大学 うつ治療剤
WO2016025669A1 (en) 2014-08-13 2016-02-18 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
WO2016095205A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
CN106749269B (zh) 2015-11-23 2019-01-04 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN109219606B (zh) 2016-02-12 2021-10-01 阿斯利康(瑞典)有限公司 食欲素受体调节剂的卤素取代的哌啶
CN110612291B (zh) 2017-05-03 2024-02-13 爱杜西亚药品有限公司 2-([1,2,3]三唑-2-基)-苯甲酸衍生物的制备
WO2020099511A1 (en) * 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
GB201901142D0 (en) * 2019-01-28 2019-03-20 Heptares Therapeutics Ltd OX1 Antagonists
CA3206675A1 (en) 2021-02-02 2022-08-11 Markus Von Raumer A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone
TW202400149A (zh) * 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130432A (en) 1990-12-21 1992-07-14 Syntex (U.S.A.) Inc. Process for preparing cyclic amines and intermediate products thereof
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
AU2002341123A1 (en) 2001-05-05 2002-11-18 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
WO2003002561A1 (en) * 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
SI1751111T1 (sl) 2004-03-01 2015-04-30 Actelion Pharmaceuticals Ltd. Substituirani 1,2,3,4-tetrahidroizokinolinski derivati
MX2008011647A (es) 2006-03-15 2008-09-22 Actelion Pharmaceuticals Ltd Derivados de tetrahidroisoquinolina para mejorar la funcion de la memoria.
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
JP2010540429A (ja) 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
CA2739916A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
AU2009307916A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
JP2012506374A (ja) * 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト
EA201170742A1 (ru) 2008-12-02 2012-01-30 Глэксо Груп Лимитед Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламинов и их применения
EA201170741A1 (ru) 2008-12-02 2011-12-30 Глэксо Груп Лимитед Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламина и их применения
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
JP5759470B2 (ja) 2009-10-23 2015-08-05 ヤンセン ファーマシューティカ エヌ.ベー. オレキシン受容体調節因子としての二置換オクタヒドロピロロ[3,4−c]ピロール
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ.ベー. オレキシン受容体調節因子としての縮合複素環式化合物

Also Published As

Publication number Publication date
KR20140096338A (ko) 2014-08-05
AR088692A1 (es) 2014-06-25
TW201632517A (zh) 2016-09-16
CY1117638T1 (el) 2017-04-26
CL2014000659A1 (es) 2014-08-18
ES2572703T3 (es) 2016-06-01
JP2014532753A (ja) 2014-12-08
MX2014005635A (es) 2014-06-23
US9150566B2 (en) 2015-10-06
WO2013068935A1 (en) 2013-05-16
BR112014010617B1 (pt) 2021-12-14
ZA201404189B (en) 2017-08-30
JP5718535B2 (ja) 2015-05-13
EA024106B1 (ru) 2016-08-31
EA201400553A1 (ru) 2014-10-30
AU2012335194B2 (en) 2017-05-25
PL2776430T3 (pl) 2016-09-30
CA2846568C (en) 2020-01-14
NZ625896A (en) 2016-04-29
US20150158855A1 (en) 2015-06-11
BR112014010617A8 (pt) 2017-12-26
TW201323421A (zh) 2013-06-16
KR101676930B1 (ko) 2016-11-16
EP2776430A1 (en) 2014-09-17
AU2012335194A1 (en) 2014-07-03
CN103917538A (zh) 2014-07-09
HRP20160678T1 (hr) 2016-07-15
MY167791A (en) 2018-09-26
TWI555747B (zh) 2016-11-01
HUE029239T2 (en) 2017-02-28
MX343837B (es) 2016-11-24
HK1199022A1 (zh) 2015-06-19
IL232462A (en) 2016-11-30
EP2776430B1 (en) 2016-03-16
UA112317C2 (uk) 2016-08-25
CN103917538B (zh) 2016-08-24
DK2776430T3 (en) 2016-05-09
BR112014010617A2 (pt) 2017-04-25
TWI565703B (zh) 2017-01-11
SI2776430T1 (sl) 2016-06-30
CA2846568A1 (en) 2013-05-16
IL232462A0 (en) 2014-06-30
SG11201401665WA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
IN2014CN04127A (uk)
MX354102B (es) Derivados de bencimidazol-prolina.
UA108926C2 (uk) ПІРОЛО[2,3-d]ПІРИМІДИНОВІ ІНГІБІТОРИ ТРОПОМІОЗИНЗАЛЕЖНОЇ КІНАЗИ
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
ATE483707T1 (de) 2-cyclopropylthiazolderivate
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX2010001338A (es) Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.
SG195106A1 (en) Trpv4 antagonists
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
MX2021004000A (es) Derivados de piperidina.
WO2013190508A3 (en) 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
PH12015502632A1 (en) Cxcr7 receptor modulators
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
WO2011138265A3 (en) Indole and indazole derivatives as orexin receptor antagonists
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
MX2009007429A (es) Compuestos de piridina y su uso como antagonistas de p2y12.
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
WO2010131192A3 (en) Novel oxazolidinone derivatives and their use as orexin receptor antagonists
UA112586C2 (uk) Похідні бензімідазолпроліну
MX356499B (es) Derivados de heteroarilamida novedosos que tienen propiedades antiandrogénicas.